Alto Neuroscience, Inc. (ANRO)
| Market Cap | 847.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -63.24M |
| Shares Out | 35.05M |
| EPS (ttm) | -2.19 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,411 |
| Open | 24.24 |
| Previous Close | 24.27 |
| Day's Range | 23.69 - 24.99 |
| 52-Week Range | 2.12 - 28.44 |
| Beta | 2.06 |
| Analysts | Strong Buy |
| Price Target | 29.00 (+19.93%) |
| Earnings Date | May 13, 2026 |
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 pro... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for ANRO stock is "Strong Buy." The 12-month stock price target is $29.0, which is an increase of 19.93% from the latest price.
News
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, t...
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced ...
Alto Neuroscience Transcript: Stifel 2026 Virtual CNS Forum
ALTO-207's combination therapy for TRD enables higher, faster dosing with robust efficacy and improved tolerability, supported by strong IP and rigorous trial execution. Multiple pipeline catalysts, including ALTO-101 and ALTO-300, are expected this year, with a cash runway through 2029.
Alto Neuroscience Announces $120 Million Private Placement Financing
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines ...
Alto Neuroscience Transcript: TD Cowen 46th Annual Health Care Conference
The presentation highlighted a precision psychiatry pipeline with late-stage programs for depression, TRD, bipolar depression, and cognition in schizophrenia. ALTO-207 and ALTO-101 are lead assets, with pivotal trials and key readouts expected through 2027. Biomarker-driven patient selection and innovative formulations aim to improve efficacy and tolerability.
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines ...
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #Neuroplasticity--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precisi...
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #ACNP--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicine...
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsych...
Alto Neuroscience Transcript: Jefferies London Healthcare Conference 2025
A precision medicine approach is driving multiple phase 2 programs in psychiatric disorders, with key readouts for schizophrenia, MDD, and treatment-resistant depression expected by 2026–2027. Accelerated regulatory timelines and validated biomarkers underpin the strategy.
Alto Neuroscience Transcript: Stifel 2025 Healthcare Conference
Precision psychiatry programs advance with late-stage trials in depression and cognitive impairment, leveraging biomarkers and improved trial execution. Key readouts for Alto 101, 300, and 100 are expected in 2026, while Alto 207 accelerates into phase 2B and phase 3, all supported by a strong cash position.
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines ...
Alto Neuroscience to Participate in Upcoming Investor Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines ...
Alto Neuroscience Announces $50 Million Private Placement Financing
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines...
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
SAN DIEGO, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of Alto Neuroscience, Inc. (NYSE: ANRO) shareholders against certain of its officers and d...
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of Alto Neuroscience, Inc. (NYSE: ANRO) shareholders against certain of its officers and d...
Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $ANRO #FastTrack--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medi...
Alto Neuroscience Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
The conference highlighted a precision psychiatry platform leveraging EEG and cognitive biomarkers, with a late-stage pipeline targeting cognitive impairment in schizophrenia, treatment-resistant depression, and bipolar depression. Key programs are advancing with robust trial designs, regulatory alignment, and enhanced operational rigor.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options If you purcha...
Alto Neuroscience Transcript: H.C. Wainwright 27th Annual Global Investment Conference
A precision psychiatry platform leverages biomarkers to guide CNS drug development, with late-stage trials for treatment-resistant depression, cognitive impairment in schizophrenia, and bipolar depression. Key programs use innovative biomarkers for patient selection and outcome measurement.